Status:

COMPLETED

Controlling Myopia Progression With Soft Contact Lenses

Lead Sponsor:

Johnson & Johnson Vision Care, Inc.

Conditions:

Myopia

Eligibility:

All Genders

8-12 years

Phase:

NA

Brief Summary

This study is to investigate whether novel soft contact lens optical designs can slow myopia progression.

Detailed Description

The study will be a prospective, randomized, single blind, bilateral dispensing study

Eligibility Criteria

Inclusion

  • Myopic subjects between 8 and 12 years of age.
  • The subject best sphere contact lens correction must lie between -0.75D (best of the two eyes) and -5.00D (worst of the two eyes)
  • Astigmatism must be less than or equal to 1.00D
  • 1.00D or less difference in spherical equivalent between the two eyes
  • The subject must have a best-corrected visual acuity of 0.8+2 (20/25+2) and spherical equivalent refraction visual acuity of 0.820/25) or better in both eyes
  • The subject must have at least 8D of accommodation
  • The subject and subject's parent or legal guardian must read and sign the STAEMENT OF INFORMED CONSENT
  • The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.

Exclusion

  • Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
  • Systemic disease or autoimmune disease or use of medication (e.g. antihistamine), which may interfere with lens wear.
  • Clinically significant (grade 3 or 4)corneal edema, corneal vascularization, corneal staining, or any other abnormality of the cornea, which may contraindicate contact lens wear.
  • Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection that might interfere with contact lens wear.
  • Any ocular infection.
  • Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • Any infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g. HIV)
  • Diabetes
  • Anisometropia of greater than 1.00D
  • Astigmatism of greater than 1.00D in either eye
  • Eye injury or surgery within eight weeks immediately prior to enrollment for this study.
  • Pervious refractive surgery, rigi contact lens wear, orthokeratology, keratconus or other corneal irregularity in either eye.
  • Strabismus in either eye
  • Pupil orr lid abnormality or infection in either eye
  • Central corneal scar in either eye
  • Aphakia in either eye
  • Contraindications to contact lens wear such as dry eye or history of prior unsuccessful contact lens wear.
  • History of participation in prior clinical trials aimed to control myopia progression
  • Surgically altered eyes, ocular infection of any type, ocular inflammation
  • Subject has anterior chamber angle grade 2 or narrower

Key Trial Info

Start Date :

April 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2010

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT00762970

Start Date

April 1 2007

End Date

February 1 2010

Last Update

June 19 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Tianjin Eye Hospital

Tianjin, China, 300020